000			02051 a2200565 4500
005			20250516030933.0
264		0	_c20120920
008			201209s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-011-9658-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aEl-Khoueiry, A B
245	0	0	_aA randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. _h[electronic resource]
260			_bInvestigational new drugs _cJun 2012
300			_a1175-83 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aCyclooxygenase 2 _xgenetics
650	0	4	_aCytidine Deaminase
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aNucleoside Deaminases _xgenetics
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aPhenylurea Compounds
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aRibonucleoside Diphosphate Reductase
650	0	4	_aSorafenib
650	0	4	_aTumor Suppressor Proteins _xgenetics
650	0	4	_aGemcitabine
700	1		_aRamanathan, R K
700	1		_aYang, D Y
700	1		_aZhang, W
700	1		_aShibata, S
700	1		_aWright, J J
700	1		_aGandara, D
700	1		_aLenz, H J
773	0		_tInvestigational new drugs _gvol. 30 _gno. 3 _gp. 1175-83
856	4	0	_uhttps://doi.org/10.1007/s10637-011-9658-9 _zAvailable from publisher's website
999			_c20694921 _d20694921